Health Insurers See Utilization Bouncing Back in 2022
It's rate-setting season for insurers, although the full picture for 2022 premiums won’t emerge for some months yet.
It is rate-setting season for insurers, although the full picture for 2022 premiums won’t emerge for some months yet. But in early July, Sabrina Corlette, J.D., founder and co-director of the Center on Health Insurance Reforms at Georgetown University, got a jump on what insurers might be charging by reviewing early filings for the individual market in Washington, D.C.; Maine; Oregon; Vermont; and Washington.
Corlette found a wide range of possible rate requests: from a 0.1% rate decrease by Providence Health Plan in Oregon to a proposed 28.98% increase by Premera Blue Cross in Washington.
Corlette said in a blog post for the center that the filings indicate that insurers expect utilization of healthcare services in 2022 to return to pre-pandemic levels and that some expect even higher use because of pent-up demand. Providence Health Plan, for example, has included a 7.2% “COVID-19 rebound adjustment,” Corlette reported. Insurers also are bracing for costs associated with COVID-19 long haulers and the worsening of chronic conditions because of delayed or canceled care in 2020 and this year (see our story on page 31).
The filings reveal a range of opinions on the effects of the pandemic on claims, according to Corlette’s review. Harvard Pilgrim Health Care in Maine is projecting that vaccine boosters will add 1% to 2022 claims costs, whereas Maine’s Community Health Options sees its COVID-19-related costs as decreasing by 0.5% because vaccination is less expensive than testing.
Premiums for Employer-based Health Insurance Increased by 7% in 2024, Says KFF Report
Published: October 9th 2024 | Updated: October 9th 2024The 2024 increase is the same as last year's increase for family coverage. The foundation’s annual survey of employer health benefits also found that only 18% of large employers (200 employees are more) are covering the GLP-1 weight loss drugs.
Read More
Doug Chaet of Value Evolutions Discusses Value-based Payment Models, Where They Stand and More
September 29th 2022In this episode of Tuning In to the C-Suite, Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing, the status of select payment models like bundled and episodic, and more.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
We conducted our annual State of the Industry survey in the early part of November 2023. The survey had 432 respondents, of whom 56% self-reported working for a payer organization (pharmacy benefit manager, insurer or self-insured employer), 34% for a provider organization and the remainder for government or an unspecified “other” category.
Read More
